Steven R. Hagen, Ph.D. has been promoted to vice president of pharmaceutical development and manufacturing, AMRI. He will report to chairman, president and chief executive officer, Thomas E. D’Ambra, Ph.D. Luckner G. Ulysse, Jr., Ph.D. has been promoted to vice president, chemical development from senior director, chemical development and small scale cGMP, reporting to Dr. Hagen.
   
Dr. Hagen previously served as vice president for quality and analytical chemistry, responsible for regulatory affairs for all AMRI locations. In this expanded role, he will assume leadership for the company’s chemical development, small scale cGMP manufacturing, and large scale commercial manufacturing business components, including operations in Albany/Rensselaer and Syracuse, NY and Hyderabad, India, as well as the company’s large scale manufacturing operations in Rensselaer and Aurangabad, India.
   
Dr. Hagen joined the company in 2005 as senior director of analytical quality services. Prior to AMRI, he spent more than 10 years at Pfizer in positions of increasing responsibility culminating in director of analytical research and development at Pfizer’s Global R&D Division. Before Pfizer, he managed the analytical activities at Ribi ImmunoChem Research, Inc. in support of R&D, production and quality control.
   
Dr. Ulysse, in addition to managing the company’s small scale cGMP and chemical development operations in Albany/Rensselaer and Syracuse, will integrate international development operations, including AMRI operations in Hyderabad, India. Prior to joining the company in 1999, Dr. Ulysse was senior research chemist at Advanced ChemTech Inc.  
   
“We are pleased to announce the promotions of Drs. Hagen and Ulysse into these expanded leadership roles at AMRI,” said Dr. D’Ambra. “Both of these individuals have consistently demonstrated the ability to achieve and deliver positive results from their teams and operations, as evidenced by the continued improvements to efficiencies and financial results in their departments. We believe they will continue to be drivers of successful change and growth. We wish both Drs. Hagen and Ulysse success in their new positions.”